原著・論文(審査を経た論文)

2021年

2020年

2019年

  1. A phase II study of lenalidomide consolidation and maintenance therapy after autologous PBSCT in patients with multiple myeloma.

    Fuchida SI, Sunami K, Matsumoto M, Okumura H, Murayama T, Miyamoto T, Otsuka E, Fujishima N, Izumi T, Tamaki S, Hiramatsu Y, Kuroda Y, Shimazaki C, Akashi K, Harada M, on behalf of the Japan Study Group for Cell Therapy and Transplantation (JSCT). Int J Hemato. 2019 Jan; 109(1):107-114.

  2. Tyrosine kinase inhibitor therapy prescribed for non-urologic diseases can modify PSA titers in urology patients

    Sasaki T, Franco OE, Ohishi K, Filipovich Y, Ishii K, Crawford SE, Takahashi N, Katayama N, Sugimura Y, Hayward SW. Prostate. 2019 Feb; 79(3): 259-264.

  3. Relationship between clinical course of nivolumab-related myositis and immune status in a patient with Hodgkin’s lymphoma after allogeneic hematopoietic stem cell transplantation.

    Kobayashi T, Guo Y-M, Yamashita T, Nara M, Yoshioka T, Kameoka Y, Fukuda T, Takahashi N. Int J Hematol. 2019 Mar; 109(3): 356-360.

  4. Myeloablative and reduced-intensity conditioning in HLA haploidentical peripheral blood stem cell transplantation using post-transplant cyclophosphamide.

    Sugita J, Kagaya Y, Miyamoto T, Shibasaki Y, Nagafuji K, Ota S, Furukawa T, Nara M, Akashi K, Taniguchi S, Harada M, Matsuo K, Teshima T, on behalf of the Japan Study Group for Cell Therapy and Transplantation (JSCT). Bone Marrow Transplantation. 2019 Mar; 54(3): 432-441.

  5. Efficacy and safety of tyrosine kinase inhibitors for newly diagnosed chronic-phase chronic myeloid leukemia over a 5-year period: results from the Japanese registry obtained by the New TARGET system.

    Kizaki M, Takahashi N, Iriyama N, Okamoto S, Ono T, Usui N, Inokuchi K, Nakaseko C, Kurokawa M, Sumi M, Nakamura F, Kawaguchi T, Suzuki R, Yamamoto K, Ohnishi K, Matsumura I, Naoe T, the New TARGET investigators. Int J Hematol. 2019 Apr; 109(4):426-439.

  6. Pharmacokinetics of Tacrolimus Coadministered With Letermovir in Allogeneic Hematopoietic Stem Cell Transplantation Patients.

    Guo Y-M, Abumiya M, Yamashita T, Ubukawa K and Takahashi N. Clin Pharmacol Drug Dev. 2019 Apr; 8(3): 411-412.

  7. ATP produced by anaerobic glycolysis is essential for enucleation of human erythroblasts.

    Goto T, Ubukawa K, Kobayashi I, Sugawara K, Asanuma K, Sasaki Y, Guo Y-M, Takahashi N, Sawada K, Wakui H, Nunomura W. Exp Hematol. 2019 Apr; 72: 14-26.

  8. Comparison of measurements of anti-PLA2R antibodies in Japanese patients with membranous nephropathy using in-house and commercial ELISA.

    Kaga H, Komatsuda A, Yamamoto S, Kikuchi T, Kamata M, Sato A, Odaka M, Yokota SI, Takahashi N, Wakui H. Clin Exp Nephrol. 2019 Apr; 23(4): 465-473.

  9. Dasatinib and low-intensity chemotherapy for Philadelphia chromosome-positive acute lymphoblastic leukemia in a child with Down syndrome.

    Hirabayashi S, Hasegawa D, Yamamoto K, Nishimura A, Hosoya Y, Shuo T, Kiyokawa N, Miura M, Takahashi N, Manabe A. Pediatr Blood Cancer. 2019 May; 66(5): e27612.

  10. Influence of ABCB1 polymorphisms on the pharmacokinetics and toxicity of lenalidomide in patients with multiple myeloma.

    Kobayashi T, Miura M, Abumiya M, Akamine Y, Ito F, Takahashi N. Med Oncol. 2019 May; 36(6): 55.

  11. Diagnostic and Prognostic Value of Using 18F-FDG PET/CT for the Evaluation of Bone Marrow Involvement in Peripheral T-Cell Lymphoma.

    Abe Y, Kitadate A, Usui Y, Narita K, Kobayashi H, Miura D, Takeuchi M, O'uchi E, O'uchi T, Matsue K. Clin Nucl Med. 2019 May; 44(5): e336-e341.

  12. Low hexokinase-2 expression-associated false-negative 18F-FDG PET/CT as a potential prognostic predictor in patients with multiple myeloma.

    Abe Y, Ikeda S, Kitadate A, Narita K, Kobayashi H, Miura D, Takeuchi M, Ouchi E, Ouchi T, Matsue K. Eur J Nucl Med Mol Imaging. 2019 Jun; 46(6): 1345-1350.

  13. High-throughput sequencing of IgG B-cell receptors reveals frequent usage of the rearranged IGHV4-28/ IGHJ4 gene in primary immune thrombocytopenia.

    Hirokawa M, Fujishima N, Togashi M, Saga A, Omokawa A, Saga T, Moritoki Y, Ueki S, Takahashi N, Kitaura K, Suzuki R. Sci Rep. 2019 Jun; 9(1): 8645.

  14. Effect of low platelet HLA-C expression on donor-specific antibody depletion following platelet transfusion from a corresponding HLA donor.

    Yamashita T, Ikegame K, Ito F, Kobayashi T, Nara M, Fujishima N, Anbai A, Inoue T, Kaida K, Tanaka H, Takahash N. Bone Marrow Transplant. 2019 Oct; 54(10): 1713-1716.

  15. Immunoglobulin Light Chain Amyloidosis with Severe Liver Dysfunction Accompanied by Factor X Deficiency.

    Guo Y-M, Takahashi N, Miyabe K, Yoshida M, Abe F, Yamashita T, Nara M, Yoshioka T, Ohashi K, Goto A, Takahashi N. Intern Med.2019 Oct; 58(20): 3039-3043.

  16. Membranous nephropathy with solitary polyclonal IgA deposition: A case report and literature review.

    Sawamura M, Komatsuda A, Kaga H, Saito A, Yasuda T, Wakui H, Joh K, Takahashi N. Clin Nephrol Case Stud. 2019 Oct; 7: 60-65.

  17. Thrombocytopenia Caused by a Tea Beverage of Taxus yunnanensis (Chinese Yew).

    Ubukawa K, Kameoka Y, Guo Y-M, Nara M, Watanabe A, Fujishima M, Fujishima N, Yoshioka T and Takahashi N. Intern Med. 2019 Nov; 58(21): 3153-3156.

  18. Multiparameter Flow Cytometry for the Identification of Neoplastic Plasma Cells in POEMS Syndrome with IgG-kappa Gammopathy: Successful Treatment Using Lenalidomide and Dexamethasone.

    Ikeda S, Kobayashi T, Saito M, Komatsuda A, Ubukawa K, Kameoka Y, Takahashi N. Intern Med. 2019 Dec; 58(23): 3461-3468.

  19. A Pediatric Case of Relapsing Eosinophilic Granulomatosis with Polyangiitis Successfully Treated with Mepolizumab.

    Nara M, Saito M, Abe F, Komatsuda A, Wakui H, Takahashi N. Intern Med. 2019 Dec; 58(24): 3583-3587.

  20. Induced pluripotent stem cell-based Drug Repurposing for Amyotrophic lateral sclerosis Medicine (iDReAM) study: protocol for a phase I dose escalation study of bosutinib for amyotrophic lateral sclerosis patients.

    Imamura K, Izumi Y, Banno H, Uozumi R, Morita S, Egawa N, Ayaki T, Nagai M, Nishiyama K, Watanabe Y, Hanajima R, Oki R, Fujita K, Takahashi N, Ikeda T, Shimizu A, Morinaga A, Hirohashi T, Fujii Y, Takahashi R, Inoue H. BMJ Open. 2019 Dec; 9(12): e033131.

2018年

  1. Phase II clinical trial of lenalidomide and dexamethasone therapy in Japanese elderly patients with newly diagnosed multiple myeloma to determine optimal plasma concentration of lenalidomide.

    Kobayashi T, Miura M, Niioka T, Abumiya M, Ito F, Kobayashi I, Ikeda S, Yoshioka T, Kameoka Y, Takahashi N. Ther Drug Monit. 2018 Feb 27. doi: 10.1097/FTD.0000000000000499. [Epub ahead of print]

  2. Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Single-Group, Phase 2, Open-Label Study.

    Mahon FX, Boquimpani C, Kim DW, Benyamini N, Clementino NCD, Shuvaev V, Ailawadhi S, Lipton JH, Turkina AG, De Paz R, Moiraghi B, Nicolini FE, Dengler J, Sacha T, Takahashi N, Fellague-Chebra R, Acharya S, Wong S, Jin Y, Hughes TP. Ann Intern Med. 2018 Apr 3;168(7):461-470. doi: 10.7326/M17-1094. Epub 2018 Feb 20.

  3. Hypoxia-inducible KDM3A addiction in multiple myeloma.

    Ikeda S, Kitadate A, Abe F, Takahashi N, Tagawa H. Blood Adv. 2018 Feb 27;2(4):323-334. doi: 10.1182/bloodadvances.2017008847.

  4. The potential role of clarithromycin addition to lenalidomide and dexamethasone therapy (BiRd) in multiple myeloma.

    Kobayashi T, Miura M, Abumiya M, Niioka T, Kanno S, Takahashi N. Ann Hematol. 2018 Feb 9. doi: 10.1007/s00277-018-3270-4. [Epub ahead of print] No abstract available.

  5. Different clonal dynamics of chronic myeloid leukaemia between bone marrow and the central nervous system.

    Ogawa M, Yokoyama K, Hirano M, Jimbo K, Ochi K, Kawamata T, Ohno N, Shimizu E, Yokoyama N, Yamaguchi R, Imoto S, Uchimaru K, Takahashi N, Miyano S, Imai Y, Tojo A. Br J Haematol. 2017 Dec 19. doi: 10.1111/bjh.15065. [Epub ahead of print] No abstract available.

  6. [Refractory CD20-positive peripheral T-cell lymphoma showing loss of CD20 expression after rituximab therapy and gain of CD20 expression after administration of vorinostat and gemcitabine].

    Teshima K, Ohyagi H, Kume M, Takahashi S, Saito M, Takahashi N. Rinsho Ketsueki. 2017;58(11):2227-2231. doi: 10.11406/rinketsu.58.2227. Japanese.

  7. Therapeutic drug monitoring of ponatinib using a simple high-performance liquid chromatography method in Japanese patients.

    Abumiya M, Miura M, Takahashi N. Leuk Res. 2018 Jan;64:42-45. doi: 10.1016/j.leukres.2017.11.012. Epub 2017 Nov 22.

  8. Histone deacetylase inhibitors downregulate CCR4 expression and decrease mogamulizumab efficacy in CCR4-positive mature T-cell lymphomas.

    Kitadate A, Ikeda S, Abe F, Takahashi N, Shimizu N, Matsue K, Tagawa H. Haematologica. 2018 Jan;103(1):126-135. doi: 10.3324/haematol.2017.177279. Epub 2017 Oct 12.

  9. Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis Complicated by Periaortitis and Cranial Hypertrophic Pachymeningitis: A Report of an Autopsy Case.

    Kaga H, Komatsuda A, Saito M, Nara M, Omokawa A, Togashi M, Okuyama S, Wakui H, Takahashi N. Intern Med. 2018 Jan 1;57(1):107-113. doi: 10.2169/internalmedicine.8751-16. Epub 2017 Oct 11.

  10. Deeper molecular response is a predictive factor for treatment-free remission after imatinib discontinuation in patients with chronic phase chronic myeloid leukemia: the JALSG-STIM213 study.

    Takahashi N, Tauchi T, Kitamura K, Miyamura K, Saburi Y, Hatta Y, Miyata Y, Kobayashi S, Usuki K, Matsumura I, Minami Y, Usui N, Fukuda T, Takada S, Ishikawa M, Fujimaki K, Gomyo H, Sasaki O, Ohishi K, Miyake T, Imai K, Suzushima H, Mitsui H, Togitani K, Kiguchi T, Atsuta Y, Ohtake S, Ohnishi K, Kobayashi Y, Kiyoi H, Miyazaki Y, Naoe T; Japan Adult Leukemia Study Group. Int J Hematol. 2018 Feb;107(2):185-193. doi: 10.1007/s12185-017-2334-x. Epub 2017 Sep 19.

  11. Clinicopathological and long-term prognostic features of membranous nephropathy with crescents: a Japanese single-center experience.

    Saito M, Komatsuda A, Sato R, Saito A, Kaga H, Abe F, Sawamura M, Nara M, Togashi M, Okuyama S, Wakui H, Takahashi N. Clin Exp Nephrol. 2018 Apr;22(2):365-376. doi: 10.1007/s10157-017-1465-y. Epub 2017 Aug 29.

  12. Analysis of PLA2R1 and HLA-DQA1 sequence variants in Japanese patients with idiopathic and secondary membranous nephropathy.

    Kaga H, Komatsuda A, Omokawa A, Okuyama S, Mori K, Wakui H, Takahashi N. Clin Exp Nephrol. 2018 Apr;22(2):275-282. doi: 10.1007/s10157-017-1471-0. Epub 2017 Aug 28.

  13. Correlation of plasma concentration and adverse effects of bosutinib: standard dose or dose-escalation regimens of bosutinib treatment for patients with chronic myeloid leukemia.

    Mita A, Abumiya M, Miura M, Niioka T, Takahashi S, Yoshioka T, Kameoka Y, Takahashi N. Exp Hematol Oncol. 2018 Apr 13;7:9. doi: 10.1186/s40164-018-0101-1. eCollection 2018.

  14. Switching to nilotinib is associated with deeper molecular responses in chronic myeloid leukemia chronic phase with major molecular responses to imatinib: STAT1 trial in Japan.

    Noguchi S, Nakaseko C, Nishiwaki K, Ogasawara H, Ohishi K, Tokuhira M, Noguchi M, Kimura H, Handa H, Mitani K, Miura M, Wakita H, Takahashi N; STAT study group. Int J Hematol. 2018 Aug;108(2):176-183. doi: 10.1007/s12185-018-2459-6. Epub 2018 Apr 30.

  15. Effects of polymorphisms in NR1I2, CYP3A4, and ABC transporters on the steady-state plasma trough concentrations of bosutinib in Japanese patient with chronic myeloid leukemia.

    Abumiya M, Mita A, Takahashi S, Yoshioka T, Kameoka Y, Takahashi N, Miura M. Med Oncol. 2018 May 7;35(6):90. doi: 10.1007/s12032-018-1146-z.

  16. Influence of CYP3A5 genetic differences in tacrolimus on quantitative interstitial fibrosis and long-term graft function in kidney transplant recipients.

    Komine N, Satoh S, Saito M, Numakura K, Inoue T, Tsuruta H, Narita S, Komatsuda A, Nanjo H, Kagaya H, Niioka T, Miura M, Mitobe Y, Habuchi T. Int Immunopharmacol. 2018 May;58:57-63. doi: 10.1016/j.intimp.2018.03.004. Epub 2018 Mar 15.

  17. R-High-CHOP/CHASER/LEED with autologous stem cell transplantation in newly diagnosed mantle cell lymphoma: JCOG0406 STUDY.

    Ogura M, Yamamoto K, Morishima Y, Wakabayashi M, Tobinai K, Ando K, Uike N, Kurosawa M, Gomyo H, Taniwaki M, Nosaka K, Tsukamoto N, Shimoyama T, Fukuhara N, Yakushijin Y, Ohnishi K, Miyazaki K, Sawada K, Takayama N, Hanamura I, Nagai H, Kobayashi H, Usuki K, Kobayashi N, Ohyashiki K, Utsumi T, Kumagai K, Maruyama D, Ohmachi K, Matsuno Y, Nakamura S, Hotta T, Tsukasaki K; Japan Clinical Oncology Group- Lymphoma Study Group (JCOG-LSG). Cancer Sci. 2018 Sep;109(9):2830-2840. doi: 10.1111/cas.13719. Epub 2018 Jul 28.

  18. Safety and efficacy of high-dose ranimustine (MCNU) containing regimen followed by autologous stem cell transplantation for diffuse large B-cell lymphoma.

    Kameoka Y, Akagi T, Murai K, Noji H, Kato Y, Sasaki O, Ito S, Ishizawa K, Ishida Y, Ichinohasama R, Harigae H, Takahashi N. Int J Hematol. 2018 Nov;108(5):510-515. doi: 10.1007/s12185-018-2508-1. Epub 2018 Jul 24.

  19. The localization of α-synuclein in the process of differentiation of human erythroid cells.

    Araki K, Sugawara K, Hayakawa EH, Ubukawa K, Kobayashi I, Wakui H, Takahashi N, Sawada K, Mochizuki H, Nunomura W. Int J Hematol. 2018 Aug;108(2):130-138. doi: 10.1007/s12185-018-2457-8. Epub 2018 Apr 24.

  20. Disappearance of a thrombotic microangiopathy-like glomerular lesion in a patient with a placental site trophoblastic tumor after hysterectomy.

    Sawamura M, Komatsuda A, Nara M, Togashi M, Wakui H, Takahashi N. Clin Nephrol Case Stud. 2018 Sep 20;6:27-30. doi: 10.5414/CNCS109440. eCollection 2018.

  21. Identification of a two-SNP PLA2R1 Haplotype and HLA-DRB1 Alleles as Primary Risk Associations in Idiopathic Membranous Nephropathy.

    Latt KZ, Honda K, Thiri M, Hitomi Y, Omae Y, Sawai H, Kawai Y, Teraguchi S, Ueno K, Nagasaki M, Mabuchi A, Kaga H, Komatsuda A, Tokunaga K, Noiri E. Sci Rep. 2018 Oct 22;8(1):15576. doi: 10.1038/s41598-018-33612-7.

  22. Treatment-free remission after two-year consolidation therapy with nilotinib in patients with chronic myeloid leukemia: STAT2 trial in Japan.

    Takahashi N, Nishiwaki K, Nakaseko C, Aotsuka N, Sano K, Ohwada C, Kuroki J, Kimura H, Tokuhira M, Mitani K, Fujikawa K, Iwase O, Ohishi K, Kimura F, Fukuda T, Tanosaki S, Takahashi S, Kameoka Y, Nishikawa H, Wakita H; STAT study group. Haematologica. 2018 Nov;103(11):1835-1842. doi: 10.3324/haematol.2018.194894. Epub 2018 Jul 5.

  23. Released washed platelet concentrates are effective and safe in patients with a history of transfusion reactions.

    Fujiwara SI, Fujishima N, Kanamori H, Ito M, Sugimoto T, Saito S, Sakaguchi T, Nagai K, Masuoka H, Nagai K, Morita A, Kino S, Tanaka A, Hasegawa Y, Yokohama A, Fujino K, Makino S, Matsumoto M, Takeshita A, Muroi K. Transfus Apher Sci. 2018 Dec;57(6):746-751. doi: 10.1016/j.transci.2018.09.001. Epub 2018 Sep 7.

  24. Unsuppressed serum albumin levels may jeopardize the clinical relevance of the international staging system to patients with light chain myeloma.

    Kasamatsu T, Ozaki S, Saitoh T, Konishi J, Sunami K, Itagaki M, Asaoku H, Cho T, Handa H, Hagiwara S, Wakayama T, Negoro A, Takezako N, Harada N, Kuroda Y, Nakaseko C, Miyake T, Inoue N, Hata H, Shimazaki C, Ohno T, Kuroda J, Murayama T, Kobayashi T, Abe M, Ishida T, Nagura E, Shimizu K. Hematol Oncol. 2018 Dec;36(5):792-800. doi: 10.1002/hon.2559. Epub 2018 Sep 19.

2017年

  1. Quantification of Interstitial Fibrosis in Renal Allografts and Clinical Correlates of Long-Term Graft Function.

    Nara M, Komatsuda A, Numakura K, Saito M, Inoue T, Niioka T, Miura M, Mitobe Y, Okuyama S, Takahashi N, Habuchi T, Satoh S. Am J Nephrol. 2017;46(3):187-194. doi: 10.1159/000479983. Epub 2017 Aug 22.

  2. Relationship Between the CYP2C19 Phenotype Using the Voriconazole-to-Voriconazole N-Oxide Plasma Concentration Ratio and Demographic and Clinical Characteristics of Japanese Patients With Different CYP2C19 Genotypes.

    Niioka T, Fujishima N, Abumiya M, Yamashita T, Ubukawa K, Nara M, Fujishima M, Takahashi N, Miura M. Ther Drug Monit. 2017 Oct;39(5):514-521. doi: 10.1097/FTD.0000000000000441.

  3. Successful management of splenomegaly with ruxolitinib prior to allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia transformed from post-polycythemia vera myelofibrosis.

    Fujishima M, Fujishima N, Kitadate A, Guo Y, Watanabe A, Ubukawa K, Nara M, Yoshioka T, Kameoka Y, Takahashi N. Rinsho Ketsueki. 2017;58(7):743-748. doi: 10.11406/rinketsu.58.743. Japanese.

  4. Clinical impact of pre-transplant gut microbial diversity on outcomes of allogeneic hematopoietic stem cell transplantation

    Doki N, Suyama M, Sasajima S, Ota J, Igarashi A, Mimura I, Morita H, Fujioka Y, Sugiyama D, Nishikawa H, Shimazu Y, Suda W, Takeshita K, Atarashi K, Hattori M, Sato E, Watakabe-Inamoto K, Yoshioka K, Najima Y, Kobayashi T, Kakihana K, Takahashi N, Sakamaki H, Honda K, Ohashi K. Ann Hematol. 2017 Sep;96(9):1517-1523. doi: 10.1007/s00277-017-3069-8. Epub 2017 Jul 21.

  5. Ponatinib in Japanese patients with Philadelphia chromosome-positive leukemia, a phase 1/2 study.

    Tojo A, Kyo T, Yamamoto K, Nakamae H, Takahashi N, Kobayashi Y, Tauchi T, Okamoto S, Miyamura K, Hatake K, Iwasaki H, Matsumura I, Usui N, Naoe T, Tugnait M, Narasimhan NI, Lustgarten S, Farin H, Haluska F, Ohyashiki K. Int J Hematol. 2017 Sep;106(3):385-397. doi: 10.1007/s12185-017-2238-9. Epub 2017 Apr 25.

  6. Long-term treatment with bosutinib in a phase 1/2 study in Japanese chronic myeloid leukemia patients resistant/intolerant to prior tyrosine kinase inhibitor treatment.

    Takahashi N, Nakaseko C, Kobayashi Y, Miyamura K, Ono C, Koide Y, Fujii Y, Ohnishi K. Int J Hematol. 2017 Sep;106(3):398-410. doi: 10.1007/s12185-017-2239-8. Epub 2017 Apr 13.

  7. Effects of Denosumab on Bone Metabolic Markers and Bone Mineral Density in Patients Treated with Glucocorticoids.

    Sawamura M, Komatsuda A, Togashi M, Wakui H, Takahashi N. Intern Med. 2017;56(6):631-636. doi: 10.2169/internalmedicine.56.7797. Epub 2017 Mar 17.

  8. Evaluation of the safety and efficacy of recombinant soluble thrombomodulin for patients with disseminated intravascular coagulation associated with acute leukemia: multicenter prospective study by the Tohoku Hematology Forum.

    Yokoyama H, Takahashi N, Katsuoka Y, Inomata M, Ito T, Meguro K, Kameoka Y, Tsumanuma R, Murai K, Noji H, Ishizawa K, Ito S, Onishi Y, Harigae H; Tohoku Hematology Forum. Int J Hematol. 2017 May;105(5):606-613. doi: 10.1007/s12185-017-2190-8. Epub 2017 Feb 7.

  9. Hypoxia-inducible microRNA-210 regulates the DIMT1-IRF4 oncogenic axis in multiple myeloma.

    Ikeda S, Kitadate A, Abe F, Saitoh H, Michishita Y, Hatano Y, Kawabata Y, Kitabayashi A, Teshima K, Kume M, Takahashi N, Tagawa H. Cancer Sci. 2017 Apr;108(4):641-652. doi: 10.1111/cas.13183. Epub 2017 Apr 20.

  10. Trough concentration and ABCG2 polymorphism are better to predict imatinib response in chronic myeloid leukemia: a meta-analysis.

    Jiang ZP, Zhao XL, Takahashi N, Angelini S, Dubashi B, Sun L, Xu P. Pharmacogenomics. 2017 Jan;18(1):35-56. doi: 10.2217/pgs-2016-0103. Epub 2016 Dec 19.

  11. Histone deacetylase inhibitors inhibit metastasis by restoring a tumor suppressive microRNA-150 in advanced cutaneous T-cell lymphoma.

    Abe F, Kitadate A, Ikeda S, Yamashita J, Nakanishi H, Takahashi N, Asaka C, Teshima K, Miyagaki T, Sugaya M, Tagawa H. Oncotarget. 2017 Jan 31;8(5):7572-7585. doi: 10.18632/oncotarget.13810.

  12. Assessing the safety and efficacy of ruxolitinib in a multicenter, open-label study in Japanese patients with myelofibrosis.

    Komatsu N, Kirito K, Shimoda K, Ishikawa T, Ohishi K, Ohyashiki K, Takahashi N, Okada H, Amagasaki T, Yonezu T, Akashi K. Int J Hematol. 2017 Mar;105(3):309-317. doi: 10.1007/s12185-016-2130-z. Epub 2016 Nov 10. Erratum in: Int J Hematol. 2017 Mar;105(3):387.

  13. Clinicopathological characteristics of malignant lymphoma in patients with hepatitis C virus infection in the Tohoku district in Eastern Japan.

    Tajima K, Takahashi N, Ishizawa K, Murai K, Akagi T, Noji H, Sasaki O, Wano M, Itoh J, Kato Y, Shichishima T, Harigae H, Ishida Y; Tohoku Hematology Forum. Leuk Lymphoma. 2017 Jun;58(6):1509-1511. doi: 10.1080/10428194.2016.1236376. Epub 2016 Oct 10.

  14. Long-term prognosis of AL and AA renal amyloidosis: a Japanese single-center experience.

    Ozawa M, Komatsuda A, Ohtani H, Nara M, Sato R, Togashi M, Takahashi N, Wakui H. Clin Exp Nephrol. 2017 Apr;21(2):212-227. doi: 10.1007/s10157-016-1271-y. Epub 2016 Apr 26.